Home
»
Press Room
»
Vaccine Adjuvants Market Size To Reach $5.96Bn By 2033

Vaccine Adjuvants Market Size To Reach $5.96 Billion By 2033

January 2026 | Report Format: Electronic (PDF)

Vaccine Adjuvants Market Growth & Trends

The global vaccine adjuvants market size is expected to reach USD 5.96 billion by 2033, registering a CAGR of 5.60% from 2026 to 2033, according to a new report by Grand View Research, Inc. The significance of adjuvant research in the development of vaccines has increased gradually due to inadequate immunogenicity of innovative vaccine antigens. In addition, the growing focus on long-lasting immunization effect against existing and emerging diseases is expected to boost the demand for vaccine adjuvants.

Furthermore, rising prevalence of cervical cancer is anticipated to boost the market. According to NCBI, around 15,000 females die every year due to cervical cancer. There are certain companies developing vaccine adjuvants for this type of cancer in order to enhance the efficacy, such as AS04 adjuvant-adsorbed (human papillomavirus vaccine) by GSK, which boosts the immune response for a longer duration.

key Request a free sample copy or view report summary: Vaccine Adjuvants Market Report

Vaccine Adjuvants Market Report Highlights

The particulate segment held the largest market share of 29.84% in 2025, primarily due to its strong ability to enhance both humoral and cellular immune responses, making vaccines more effective.
The infectious diseases segment accounted for the largest revenue share of 61.82% in 2025, driven by the increasing prevalence of viral and bacterial infections worldwide. Rising demand for vaccines against diseases such as influenza, hepatitis, and COVID-19 has significantly contributed to market growth.
The intramuscular segment held the largest revenue share of 33.78% in 2025, driven by its established use in delivering vaccines effectively and safely across diverse patient populations. This route allows efficient absorption of adjuvanted vaccines, leading to strong immune responses.
North America vaccine adjuvants industry dominated the global market in 2025 with the largest revenue share of 39.32%. This large share is attributed to its advanced vaccine development ecosystem and strong presence of leading pharmaceutical and biotechnology companies.